Economic Times | FDA grants Breakthrough Therapy designation to Novartis' serelaxin (RLX030 ... FierceBiotech Basel, June 21, 2013 - Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to RLX030 (serelaxin), an investigational treatment for patients with acute heart failure (AHF). The FDA ... Novartis heart failure drug gets FDA incentives US FDA deems Novartis' heart failure candidate a 'breakthrough' Serelaxin, Experimental Heart Drug From Norvartis, Obtains FDA Breakthrough ... |
